ArticleInflammopharmacology2026
Idebenone attenuates sciatic nerve ligation-induced neuropathic pain through modulating antioxidant and anti-inflammatory mechanisms in rats.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Neuropathic pain is a complex clinical condition arising from damage to or dysfunction of the peripheral or central nervous system. This study aimed to investigate the therapeutic potential of idebenone, a compound with potent antioxidant and anti-inflammatory properties, in a rat model of neuropathic pain induced by chronic constriction injury (CCI) of the sciatic nerve, and to elucidate its underlying mechanisms through biochemical, electrophysiological, and histopathological analyses.A total of 42 male Sprague-Dawley rats were randomly allocated into six groups: Sham, CCI, idebenone 50 mg/kg, idebenone 100 mg/kg, idebenone 200 mg/kg, and pregabalin (10 mg/kg). Following 14 days of treatment, thermal and mechanical hyperalgesia were assessed using the hot plate and paw withdrawal tests. Biochemical analyses included the determination of serum levels of superoxide dismutase (SOD), glutathione peroxidase (GPx), malondialdehyde (MDA), tumor necrosis factor-alpha (TNF-α), and interleukin-10 (IL-10), while electrophysiological, histopathological, and stereological evaluations were conducted to assess nerve tissue alterations.Idebenone treatment significantly attenuated both thermal and mechanical hyperalgesia induced by CCI. Moreover, idebenone increased GPx, SOD, and IL-10 levels, while reducing MDA and TNF-α levels. Electrophysiologically, idebenone enhanced compound muscle action potential amplitude without significantly affecting latency. Histopathological findings indicated that idebenone did not significantly alter the number of myelinated axons but was unable to prevent the CCI-induced reduction in myelinated axon area. Overall, idebenone exhibited antioxidant, anti-inflammatory, and neuroprotective effects, as evidenced by the modulation of oxidative stress markers, suppression of pro-inflammatory cytokines, enhancement of anti-inflammatory responses, and improvement in functional nerve parameters.These findings suggest that idebenone may represent a promising therapeutic candidate for neuropathic pain; however, further clinical studies are warranted to establish its efficacy and translational potential in human subjects.
Indexed as
Identifiers
42424027What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.